Depressive Disorder, Major Clinical Trial
— IPT-GinMDOfficial title:
Effectiveness of Interpersonal Psychotherapy Group (IPT-G) as an add-on Strategy in the Treatment of Major Depression
Verified date | March 2021 |
Source | Hospital de Clinicas de Porto Alegre |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Although antidepressants are the primary treatment for major depression, response and remission rates are unsatisfactory. The primary objective of this study is to identify if adding interpersonal group therapy (IPT-G) to the usual psychopharmacological and clinical management treatment will improve depressive symptoms in major depression outpatients.
Status | Terminated |
Enrollment | 18 |
Est. completion date | March 20, 2021 |
Est. primary completion date | April 20, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Diagnosis of Major Depressive Episode evaluated by the MINI-plus instrument. 2. Patients attending the depression outpatient clinic (HCPorto Alegre) for 6 months or more 3. History of two previous appropriate antidepressant treatments (dose: equivalent of 75 mg / day of amitriptyline and time: the minimum of four weeks) 4. Beck Depression Inventory scores above 18. Exclusion Criteria: 1. Patients with bipolar disorder 2. Patients with substance abuse disorder, 3. Patients with risk of suicide 4. Patients with antisocial personality disorder 5. Patients with psychotic syndrome, 6. Patients with intellectual disability 7. Patients receiving some kind of psychotherapy at the present time and in the last four weeks. 8. Patients who are unable to communicate. 9. Patients with Dismissive Attachment Style |
Country | Name | City | State |
---|---|---|---|
Brazil | Hospital de Clinicas de Porto Alegre | Porto Alegre | Rio Grande Do Sul |
Lead Sponsor | Collaborator |
---|---|
Hospital de Clinicas de Porto Alegre |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of Depression symptoms | The Beck Depression Inventory (BDI- II) brazilian version is an self-evaluation instrument, that the scale total scores aims to identify and quantify mild, moderate and severe depression. The patient is invited to answer how he has felt in the last week.
The scale consists in 21 items including symptoms and attitudes, whose intensity varies from 0 to 3. The items refer to sadness, pessimism, past failure, lack of satisfaction, loss of pleasure, feelings of guilt, sense of punishment, self-steam, self-criticism, thoughts or desires of suicide, crying, agitation, loss of interest, indecision, devaluation, lack of energy, change in sleep patterns, irritability, changes in appetite, concentration difficulty, fatigue, loss of interest in sex. For patients diagnosed with Major Depression, the cut points are: 0-13 minimum, 14-19 mild depression, 20-28 moderate depression, 29-63 severe depression. |
14 weeks | |
Secondary | Rate of Anxiety symptoms | The Beck Anxiety Inventory (BAI) brazilian version is a self-evaluation scale, total scores consists in 21 questions about how the individual has felt in the last week, expressed in common anxiety symptoms, such as sweating and feelings of anguish. The possible answers are: no, slightly, moderately and severely. The scores are: 0-10 minimum degree of anxiety, 11-19 mild anxiety, 20-30 moderate anxiety, 31-63 severe anxiety. | 14 weeks | |
Secondary | Rate of Quality of life domains | Differences in the World Health Organization Quality of life abbreviated questionaire instrument (WHOQOL-Bref) brazilian version scale scores in four domains (Physical, Psychological, Social Relationships and Environmental).
Consists in 26 questions (each with a scale of Likert type composed of five degrees of intensity), two of them related to overall quality of life and health status and 24 facets of quality of life in general. The results can be: needs to improve (1 to 2,9), regular (3 to 3,9), good (4 to 4,9) and very good (5). |
14 weeks | |
Secondary | Rate of Social support | Difference in the Social Support Scale (MOS) validated for Brazil scores. Composed of self-applied items, multiple choice with a score of 1 to 5 (Likert scale) evaluates the perception of individuals on social support in health contexts. It consists in 19 items distributed in 4 dimensions: positive social interaction, possible social support, affective social support, emotional social support and informational social support. The patient should answer to each option: never, rarely, sometimes, often or always. In the end, the results are transformed in a punctuation of 0 to 100. | 14 weeks | |
Secondary | Rate of Resilience | Difference in the Brief Resilience Scale (BRS) total scores. The self-evaluation scale is a short version validated for Portuguese in Brazil and it is composed of 14 items, in the Likert format, with the score 1 to 7 for each question. It evaluates the perception of individuals about psychological characteristics linked to resilience. Higher overall scores indicate greater resilience. It is organized in 6 factors: self perception, future planning, social competences, family cohesion, social resources and structured style. | 14 weeks | |
Secondary | Style of Attachment | Difference in the Adult Attachment Scale (AAS-R) scores. The Portuguese version will be used, which has previously been used in the Brazilian population. It is a self-evaluation scale that consists in 18 items, marked on a Likert scale of 5 points. It measures the attachment style of the adults defined according to 3 dimensions: anxiety, comfort with proximity and confidence in others. | 14 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05915013 -
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
|
Phase 1 | |
Completed |
NCT04469322 -
Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression
|
N/A | |
Recruiting |
NCT05415397 -
Treating Immuno-metabolic Depression With Anti-inflammatory Drugs
|
Phase 3 | |
Recruiting |
NCT05988333 -
Psychoeducational Intervention for Families With a Member Affected by Major Depression
|
N/A | |
Completed |
NCT02919501 -
Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder
|
Phase 2 | |
Completed |
NCT00976560 -
Clinical Study to Test a New Drug to Treat Major Depression
|
Phase 2 | |
Recruiting |
NCT05518149 -
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
|
Phase 3 | |
Not yet recruiting |
NCT06303076 -
Tizanidine vs. Zolpidem in Primary Insomnia: A Randomized Trial
|
Phase 4 | |
Not yet recruiting |
NCT05901571 -
Acupuncture and Escitalopram for Treating Major Depression Clinical Study
|
N/A | |
Suspended |
NCT02546024 -
Predictors of Treatment Response in Late-onset Major Depressive Disorder
|
N/A | |
Completed |
NCT02452892 -
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
|
N/A | |
Completed |
NCT01583400 -
Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial
|
N/A | |
Completed |
NCT01407575 -
Buprenorphine for Treatment Resistant Depression
|
Phase 3 | |
Completed |
NCT01152996 -
Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study
|
Phase 3 | |
Enrolling by invitation |
NCT00762866 -
Psychiatric Genotype/Phenotype Project Repository
|
||
Completed |
NCT00384033 -
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT00369343 -
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
|
Phase 3 | |
Completed |
NCT00366652 -
Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects
|
Phase 3 | |
Completed |
NCT00149643 -
Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence
|
Phase 2 | |
Completed |
NCT00316160 -
Sexual Functioning Study With Antidepressants
|
Phase 4 |